SCHEMBL1855362

SCHEMBL1855362

CC(c1cc[c]cc1)N1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.53
CHRM1 P11229 1/20 0.53
CYP2D6 P10635 2/20 0.47
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MC4R P32245 1/20 0.42
CYP19A1 P11511 1/20 0.41
OPRD1 P41143 7/20 0.38
SLC6A4 P31645 5/20 0.37
SLC6A2 P23975 4/20 0.37
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 1/20 0.36
KCNH2 Q12809 1/20 0.35
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030261 0.82 CYP2D6 (0.52) CHRM2CHRM1CYP2D6MC4ROPRD1
SCHEMBL6233324 0.81 CYP2D6 (0.50) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL20883792 0.81 CHRM2 (0.59) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL3950480 0.81 CYP2D6 (0.73) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL42790 0.81 CYP2D6 (0.73) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL28140496 0.81 MEN1 (0.46) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL3956861 0.81 CYP2D6 (0.73) CHRM2CHRM1CYP2D6MEN1KMT2A
SCHEMBL4155278 0.80 CHRM2 (0.48) CHRM2CHRM1CYP2D6MEN1KMT2A
Hydrochloric Acid SCHEMBL4811700 0.79 CYP2D6 (0.70) CHRM2CHRM1CYP2D6MEN1KMT2A
Hydrochloric Acid SCHEMBL4813790 0.79 CYP2D6 (0.70) CHRM2CHRM1CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017034377-A1 PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) DONG-A ST CO., LTD. (KR) 2017-03-02 WO claimed
US-20170057955-A1 Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2017-03-02 US claimed
EP-0836613-B1 WATER-SOLUBLE ADENOSINE KINASE INHIBITORS METABASIS THERAPEUTICS INC (US) 2005-05-25 EP claimed
CN-108699064-B Hexahydropyrazino-triazinone derivatives as kinase inhibitors UCB生物制药私人有限公司 2021-09-14 CN disclosed
CN-106459046-B Pyrazolo pyridine derivatives as kinase inhibitor UCB生物制药私人有限公司 2019-01-08 CN disclosed
CN-108699064-A Hexahydropyrazine and triazone derivatives as kinase inhibitor UCB生物制药私人有限公司 2018-10-23 CN disclosed
CN-105008360-B The Pyrazolopyrimidine derivative of therapeutic activity UCB生物制药私人有限公司 2017-09-19 CN disclosed
CN-106559992-A As the bicyclic heteroaromatic derivative for condensing of kinase inhibitor UCB生物制药私人有限公司 2017-04-05 CN disclosed
CN-106507674-A Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB生物制药私人有限公司 2017-03-15 CN disclosed
WO-2017034377-A1 PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) DONG-A ST CO., LTD. (KR) 2017-03-02 WO disclosed
US-20170057955-A1 Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) DONG-A ST CO., LTD. (KR) 2017-03-02 US disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed
EP-0836613-B1 WATER-SOLUBLE ADENOSINE KINASE INHIBITORS METABASIS THERAPEUTICS INC (US) 2005-05-25 EP disclosed
US-5795977-A Water soluble adenosine kinase inhibitors METABASIS THERAPEUTICS, INC. (US) 1998-08-18 US disclosed
EP-0836613-A1 WATER-SOLUBLE ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1998-04-22 EP disclosed
US-5726302-A SUBSTITUTED 4-AMINO PYRROLO(2,3-D) PYRIMIDINE AND PYRAZOLO(3,4-D) PYRIMIDINE NUCLEOSIDE ANALOGS GENSIA INC. (US) 1998-03-10 US disclosed
WO-1996040707-A1 WATER-SOLUBLE ADENOSINE KINASE INHIBITORS GENSIA SICOR (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170057955-A1 Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) KDM1B, KDM1A, KDM3B CHRM2 3095/4885CHRM1 2669/4885CYP2D6 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.